Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 3/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.42 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5534480 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL8674659 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL7752682 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL3427004 | 1.00 | SIGMAR1 (0.56) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL25310908 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL1007371 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL1006265 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL1006136 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL1006966 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A | |
| SCHEMBL5542454 | 0.97 | SIGMAR1 (0.60) | SIGMAR1CYP1A2KDM5APHF8KDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282818-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION,INCORPORATED (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2023211883-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-11-02 | — | — | WO | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011071674-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2011-06-16 | — | — | WO | disclosed |
| CN-102056961-A | Asymmetric cyclic diester compounds | FERRO CORP | 2011-05-11 | — | — | CN | disclosed |
| EP-2307476-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100113664-A1 | Asymmetric Cyclic Diester Compounds | FERRO CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2009152068-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090312470-A1 | Asymmetric Cyclic Diester Compounds | FERRO CORPORATION (US) | 2009-12-17 | — | — | US | disclosed |
| US-7091357-B2 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | BASF AKTIENGESELLSCHAFT (DE) | 2004-05-20 | — | — | US | disclosed |
| US-20030225142-A1 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-12-04 | — | — | US | disclosed |
| EP-0821049-B1 | Cyclopentyl compounds | ROLIC AG (CH) | 2001-01-10 | — | — | EP | disclosed |
| US-5759443-A | Cyclopentyl derivatives | ROLIC AG (CH) | 1998-06-02 | — | — | US | disclosed |
| EP-0821049-A1 | Cyclopentyl compounds | Rolic AG (CH) | 1998-01-28 | — | — | EP | disclosed |
| US-4987132-A | PLATELET ACTIVATING FACTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| EP-0279681-A2 | Saturated heterocyclic carboxamide derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225142-A1 | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies | CHRNA4, CHRNA2, CHRNA5 | SIGMAR1 152/4885CYP1A2 744/4885KDM5A 2241/4885 |
| US-20250282818-A1 | SYRBACTIN MACROLACTAMS AND UNNATURAL ANALOGS AS PROTEASOME INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA AND CHEMOENZYMATIC SYNTHESIS THEREOF | PSMB10, PSMB1, PSMB5 | SIGMAR1 4031/4885CYP1A2 4409/4885KDM5A 1016/4885 |
| US-20090312470-A1 | Asymmetric Cyclic Diester Compounds | DDT, PCNA, AADAC | SIGMAR1 2958/4885CYP1A2 31/4885KDM5A 1747/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SIGMAR1 234/4885CYP1A2 659/4885KDM5A 4851/4885 |
| US-20040097728-A1 | Method for producing anellated tetrahydro-{1h}-triazoles | CBR1, CBR3, QSOX1 | SIGMAR1 1608/4885CYP1A2 32/4885KDM5A 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.